相关实验视频

Updated: Jan 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

没有蛋白质尿和功能之间的相关性患有不可切除的肝细胞癌的患者接受阿特佐利祖马布加贝瓦西祖马布治疗:ARISE研究

Kazuomi Ueshima¹, Naoshi Nishida¹, Satoru Hagiwara¹

¹Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.

|December 11, 2025

概括

在治疗不可切除肝细胞癌的阿特佐利祖马布加贝瓦齐祖马布治疗期间的蛋白尿似乎不会影响功能. 这一发现表明,由于蛋白尿,医生应该在停止治疗贝瓦西祖马布之前权衡风险和益处.

科学领域:

在瘤学瘤学.
腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.

背景情况:

阿特佐利祖马布加贝瓦西祖马布 (Atezo + Bev) 是治疗不可切除的肝细胞癌 (uHCC) 的标准治疗方法.
蛋白尿是贝瓦西祖马布 (Bev) 的常见副作用,经常导致治疗中断.
在HHCC患者中,Bev诱导的蛋白尿和功能障碍之间的联系尚不清楚.

研究的目的:

在接受Atezo + Bev.的HHCC患者中研究蛋白尿和功能之间的关系.
分析尿蛋白肌素比率 (UPCR) 变化对治疗期间估计的淋巴细胞过率 (eGFR) 的影响.

主要方法:

对100名接受Atezo + Bev治疗的HHCC患者进行了回顾性单臂研究.
从基线对UPCR和eGFR变化之间的相关性分析.
数据是从2020年9月到2022年5月在日本金台大学医院收集的.

主要成果:

观察到UPCR的中位数最大增加为0.39和eGFR的中位数最大下降为-7.5mL/min/1.73m2.
在UPCR和eGFR变化之间的Pearson和Spearman相关系数分别为-0.16和-0.13.
蛋白尿和功能下降之间没有发现显著的相关性.

结论:

在Atezo + Bev治疗期间的蛋白尿与HHCC患者的功能受损没有相关性.
目前基于蛋白尿的Bev中断指南可能需要重新评估.
在管理与蛋白尿相关的治疗决策时,医生应考虑风险-益处概况.

关键词:

它们是Atezolizumab.这是bevacizumab的治疗方法.蛋白质尿症是一种蛋白质尿症.功能功能功能不能切除的肝细胞癌.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...